Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Share-based Compensation: 2022-2025

Historic Share-based Compensation for Taysha Gene Therapies (TSHA) over the last 4 years, with Sep 2025 value amounting to $3.3 million.

  • Taysha Gene Therapies' Share-based Compensation fell 2.14% to $3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.0 million, marking a year-over-year increase of 9.53%. This contributed to the annual value of $13.1 million for FY2024, which is 65.76% up from last year.
  • According to the latest figures from Q3 2025, Taysha Gene Therapies' Share-based Compensation is $3.3 million, which was up 2.98% from $3.2 million recorded in Q2 2025.
  • In the past 5 years, Taysha Gene Therapies' Share-based Compensation registered a high of $5.3 million during Q1 2022, and its lowest value of $1.7 million during Q1 2023.
  • For the 3-year period, Taysha Gene Therapies' Share-based Compensation averaged around $2.8 million, with its median value being $3.2 million (2024).
  • Per our database at Business Quant, Taysha Gene Therapies' Share-based Compensation crashed by 68.57% in 2023 and then skyrocketed by 90.93% in 2024.
  • Taysha Gene Therapies' Share-based Compensation (Quarterly) stood at $4.1 million in 2022, then plummeted by 52.04% to $2.0 million in 2023, then soared by 63.41% to $3.2 million in 2024, then decreased by 2.14% to $3.3 million in 2025.
  • Its last three reported values are $3.3 million in Q3 2025, $3.2 million for Q2 2025, and $3.3 million during Q1 2025.